27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
The FDA has accepted for review Bristol Myers Squibb & Co's (NYSE:BMY) deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis.
- The European Medicines Agency has also validated the deucravacitinib marketing application for plaque psoriasis.
- The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 10, 2022.
- The regulatory applications are based on positive results from the pivotal POETYK PSO-1 and POETYK PSO-2 trials, which evaluated once-daily deucravacitinib versus placebo and Amgen Inc's (NASDAQ:AMGN) Otezla (apremilast).
- Deucravacitinib demonstrated significant and clinically meaningful improvements in skin clearance, symptom burden, and quality of life measures compared to placebo and Otezla.
- Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor.
- See here Benzinga's Full FDA Calendar.
- Price Action: BMY shares are down 1.02% at $55.96 during the market session on the last check Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!